{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:41:07Z","timestamp":1791009667584,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.lungcan.2010.09.011","type":"journal-article","created":{"date-parts":[[2010,10,23]],"date-time":"2010-10-23T08:18:58Z","timestamp":1287821938000},"page":"109-112","source":"Crossref","is-referenced-by-count":28,"title":["Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation"],"prefix":"10.1016","volume":"71","author":[{"given":"Umut","family":"Di\u015fel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"\u00d6ztuzcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Ayberk","family":"Be\u015fen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemile","family":"Karadeniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"K\u00f6se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Taner","family":"S\u00fcmb\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl Nihal","family":"Nursal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Abal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"\u00d6zy\u0131lkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (3)","key":"10.1016\/j.lungcan.2010.09.011_bib0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00000421-200206000-00012","article-title":"Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy)","volume":"25","author":"Koizumi","year":"2002","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2010.09.011_bib0010","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.48.1922","article-title":"Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone","volume":"48","author":"Ito","year":"2009","journal-title":"Intern Med"},{"issue":"March (3)","key":"10.1016\/j.lungcan.2010.09.011_bib0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"issue":"December (3)","key":"10.1016\/j.lungcan.2010.09.011_bib0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"issue":"December (3)","key":"10.1016\/j.lungcan.2010.09.011_bib0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"issue":"September (17)","key":"10.1016\/j.lungcan.2010.09.011_bib0030","first-page":"4297","article-title":"Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors","volume":"59","author":"Taniguchi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2010.09.011_bib0035","first-page":"61","article-title":"Sorafenib. Recent results","volume":"184","author":"Hasskarl","year":"2010","journal-title":"Cancer Res"},{"issue":"June (25)","key":"10.1016\/j.lungcan.2010.09.011_bib0040","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N Engl J Med"},{"issue":"June (6)","key":"10.1016\/j.lungcan.2010.09.011_bib0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"September (3)","key":"10.1016\/j.lungcan.2010.09.011_bib0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithel tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.lungcan.2010.09.011_bib0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2010.09.011_bib0060","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2010.09.011_bib0065","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-04-1981","article-title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer","volume":"11","author":"Chou","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500210004745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500210004745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T08:25:49Z","timestamp":1544171149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500210004745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0169500210004745"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2010.09.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}